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Rare diseases are powerful windows into biological processes and can serve as models for the
development of therapeutic strategies. The progressmade on the premature aging disorder Proge-
ria is a shining example of the impact that studies of rare diseases can have.The premature aging disorder Hutchin-
son-Gilford progeria syndrome (HGPS,
or progeria) is one of the rarest human
diseases. Yet its study over the last
decade has attracted attention from
basic scientists, clinicians, the pharma-
ceutical industry, and policy makers.
Why is the scientific community intensely
watching the activity surrounding a dis-
ease that affects a mere 350 children
worldwide (Gordon, 2013)? There are
two important reasons. First, progress
in HGPS can be viewed as a paradigm
of modern translational medicine: basic
science informing clinical medicine in a
bench-to-bedside approach to medical
discovery. Second, discoveries in rare
diseases often offer new possibilities for
understanding of cellular and organismal
mechanisms, such as normal aging and
cardiovascular disease in the case of
HGPS. This Essay summarizes advances
made in the understanding of HGPS and
discusses the implications of research
into rare diseases on basic cell biology,
understanding of physiological pro-
cesses, drug discovery, and clinical trial
design.
A Short History of HGPS
HGPS was first described by Drs. Jona-
than Hutchinson and Hastings Gilford in
1886 and 1897, respectively (Gilford,
1904; Hutchinson, 1886). For more than
100 years, its cause was a medical mys-
tery. The disease was designated as a
premature aging syndrome by Gilford400 Cell 156, January 30, 2014 ª2014 Elseviebased on the overall resemblance of
patients to aged individuals and the pres-
ence of aging-associated symptoms,
including lack of subcutaneous fat, hair
loss, joint contractures, progressive car-
diovascular disease resembling athero-
sclerosis, and death due to heart attacks
and strokes in childhood (Merideth et al.,
2008) (Figure 1).
The mapping of the disease gene re-
vealed that HGPS is a sporadic, auto-
somal dominant disease caused by a
mutation in LMNA (De Sandre-Giovannoli
et al., 2003; Eriksson et al., 2003). This
gene codes for the inner nuclear mem-
brane proteins lamins A and C, two
prominent structural components of the
eukaryotic cell nucleus. HGPS is a
member of a group of diseases called
laminopathies, resulting from mutations
throughout the LMNA gene that result
in a wide spectrum of overlapping
disorders. These include muscular dys-
trophies, a peripheral neuropathy, lipo-
dystrophy syndromes, and accelerated
aging disorders (Worman and Bonne,
2007).
The disease-causing mutation in
HGPS activates what is normally a only
sporadically used alternative splice site
in LMNA exon 11, resulting in partial
deletion of the exon (Figure 1). Although
the discovery of disease genes does
not always inform about disease mecha-
nism, the identification of an LMNA
mutation as the cause of HGPS inspired
intense basic and clinical research intor Inc.this disease and its relationship to aging.
The reason for the rapid progress in our
understanding of HGPS was that the
gene identification dovetailed with exten-
sive prior work by basic cell biologists on
the complex posttranslational processing
events of lamin A, which would turn out
to be key for understanding the HGPS
disease mechanism (Sinensky et al.,
1994).
Normally, lamin A is produced via a
prelamin intermediate whose C-terminal
cysteine residue is first modified by farne-
sylation and carboxymethylation followed
by enzymatic cleavage of the terminal 15
amino acids, including the farnesylated
cysteine, by the ZMPSTE24 endopro-
tease. However, in the HGPSmutant prel-
amin A isoform, this cleavage site is
missing as a result of the aberrant splicing
event. Thus, the HGPS mutation leads to
the accumulation of a permanently farne-
sylated, uncleaved lamin A isoform
named progerin (Figure 1). This aberrantly
modified, lamin A intermediate triggers,
by yet-to-be discovered mechanisms,
the many cellular and organismal disease
symptoms.
ARareDiseaseProvides Insight into
Fundamental Cell Biology
Elucidating the cascade of damaging
events is a critical step in the understand-
ing of any disease, and it is often crucial
for identifying candidate drug targets.
HGPS patient cells have numerous de-
fects, and studying them has become a
Figure 1. HGPS: From Genetics to Symptoms
HGPS is caused by a spontaneous point mutation in the LMNA gene, coding
for the nuclear intermediate filament proteins lamin A and C. The disease
mutation activates an alternative pre-mRNA splice site in exon 11 that results
in removal of 150 nt from the 30 end of this exon and creates an internal deletion
of 50 aa in the translated lamin A protein. The mutant protein (red), referred to
as progerin, is permanently farnesylated as the 50 aa deletion includes an
endoproteolytic cleavage site, which normally removes the farnesylated C
terminus from the wild-type protein. The farnesyl group is believed to facilitate
the association of the protein to the nuclear membrane, resulting in its accu-
mulation at the nuclear periphery. Association of progerin with the lamina
interferes with normal lamina function and triggers, via yet unknown mecha-
nisms, many of the commonly observed nuclear defects. HGPS cells also
exhibit nonnuclear defects, including altered signaling and metabolic prop-
erties. It is assumed that these cellular defects and particularly the loss of stem
cell function contribute to the prominent overt patient symptoms. (Left) Fluo-
rescently tagged progerin (green) accumulates at the periphery of patient
nuclei and alters nuclear morphology. (Right) Two progeria patients. Image
reproduced with permission, courtesy of The Progeria Research Foundation.powerful tool for both basic
scientists and clinicians to
ask questions about the roles
of major cellular processes in
health and disease (Figure 1).
Nuclear Morphology and
Function
The most overt cellular
defects in HGPS are dramatic
changes in nuclear morphol-
ogy (Eriksson et al., 2003), a
phenotype that is not surpris-
ing given the prominent archi-
tectural role of lamin A in the
nucleus. Whereas the lamin
proteins in healthy cells move
dynamically between the
nuclear lamina polymer at
the nuclear periphery and the
nucleoplasm, they become
immobilized in HGPS patient
cells, leading to thickening of
the lamina (Goldman et al.,
2004; Dahl et al., 2010).
Probably as a consequence
of these structural changes,
the mechanical properties of
HGPS nuclei are altered and
patient cells exhibit increased
stiffness compared with cells
from healthy individuals (Dahl
et al., 2010). These alterations
are likely relevant in disease
pathology, as they might
affect the response of cells in
tissues that are particularly
exposed to mechanical stress
such as the vasculature,
bone, and joints—three tis-
sues that exhibit some of the
most prominent symptoms
in HGPS patients. These
defects are of great interest
to the study of lamin biology
because despite the known
major functions of the nuclearlamins, the structural properties of the nu-
clear scaffold have remained elusive
(Burke and Stewart, 2013). For example,
it is unclear precisely how lamins poly-
merize and how they interact with amyriad
of inner nuclearmembrane complexes and
chromatin or how they transmit mechani-
cal signals to mechanosensitive genes.
Lamin mutants such as the one causing
HGPS are promising tools to begin to
elucidate fundamental aspects of nuclear
organization.DNA and Chromosome Function
Two other notable cellular defects in
HGPS patient cells are widespread alter-
ations of chromatin structure, such as
the loss of heterochromatin domains,
and changes in epigenetic markers. Using
HGPS cells as a model system, the
nucleosome-remodeling and deacetylase
complex NURD has been identified as a
mediator of both higher-order chromatin
structure and maintenance of genomic
integrity (Pegoraro et al., 2009). UsingCell 156, January 30genome-wide studies in
which the physical interac-
tions of lamins with the
genome are comparatively
mapped in wild-type and
patient cells, HGPS also
provides an opportunity to
probe lamin-genome interac-
tions, which are increasingly
recognized as key drivers of
overall genome organization
(McCord et al., 2013). HGPS
patient cells also suffer DNA
repair defects due to both
reduced recruitment of DNA
damage response (DDR) fac-
tors to sites of damage and
slowed repair kinetics (Ben-
son et al., 2010; Musich and
Zou, 2009). On the other
hand, the xeroderma pig-
mentosum group A (XPA)
protein appears aberrantly
recruited to replication forks,
promoting replication fork
stalling and activation of the
DDR (Liu et al., 2006). Pro-
gerin also appears to modu-
late telomere function and to
induce DDR signaling from
telomeres via activation of
p53 and Rb pathways (Ben-
son et al., 2010). Interestingly,
telomere dysfunction during
senescence appears to feed
back and promote pro-
gerin expression (Cao et al.,
2011a). These studies have
begun to uncover the elu-
sive mechanisms that link
nuclear structure and geno-
mic instability.
Regulatory and Stress
Response
Functional studies using ani-
mal and cellular models ofHGPS have facilitated the identification
of regulatory and stress-response path-
ways involved in HGPS development. Of
special interest is the hyperactivation of
p53 signaling in HGPS cells and in mouse
models of HGPS (Kudlow et al., 2008; Liu
et al., 2006; Varela et al., 2005). However,
the fact that phenotype alterations in
these progeroid mice are not completely
rescued in a p53 null background indi-
cates that other pathways contribute to
the generation of the observed defects., 2014 ª2014 Elsevier Inc. 401
These additional pathways may include
the attrition of adult stem cells (Espada
et al., 2008; Rosengardten et al., 2011;
Scaffidi and Misteli, 2008), the dysregula-
tion of the somatotrophic axis and several
miRNA-controlled circuits (Marin˜o et al.,
2010; Ugalde et al., 2011), the generation
of profound changes in glucose and lipid
metabolism (Marin˜o et al., 2008), and the
ATM-dependent activation of NF-kB
signaling that links nuclear lamina defects
to the systemic inflammation observed in
two different progeroid murine models
(Osorio et al., 2012).
Induced Pluripotent Stem Cells and
Their Potential
As in many diseases, tissue-specific cell
lines from HGPS patients are not easily
obtainable due to the difficulty of
performing biopsies on frail patients. The
development of patient-derived induced
pluripotent stem (iPS) cells provides
powerful tools to study differentiation
pathways of tissues affected by the dis-
ease. HGPS iPS cells have been success-
fully generated and differentiated along
multiple lineages, including the particularly
disease-relevant vascular smooth muscle
cells (VSMCs) and mesenchymal stem
cells (Zhang et al., 2011). Early experi-
ments using these cells revealed height-
ened sensitivity of HGPS mesenchymal
stemcells to stress andaberrant differenti-
ation of HGPSVMSCs (Zhang et al., 2011).
Patient-derived iPS cells have also already
been used to develop strategies that
can successfully correct the HGPS muta-
tion (Liu et al., 2011), and, as with many
other diseases, they will also be invaluable
in screening approaches to identify
possibly tissue-specific drugs. Finally,
normal and gene-corrected HGPS iPS-
derived tissue-specific cells may in the
futureprovidea foundation for cell replace-
ment therapy approaches to HGPS.
What Progeria May or May Not
Teach Us about Normal Aging
Rare diseases often reflect highly preva-
lent pathological events and provide a
unique opportunity to study physiological
processes. In the case of HGPS, the
obvious question is whether the disease
provides insights into normal aging and,
because cardiovascular failure is the
source of significant morbidity and mor-
tality, into aging-related cardiovascular
disease.402 Cell 156, January 30, 2014 ª2014 ElsevieThe similarities between HGPS and
normal aging extend to all levels, from
shared molecular features to similarities
in symptoms (Burtner and Kennedy,
2010; Lo´pez-Otı´n et al., 2013). Notably,
progerin is produced in normally aging in-
dividuals as well as in HGPS patients. This
is because the classic HGPSmutation is a
pre-mRNA splicing mutation, which acti-
vates a weak, yet sporadically used,
intronic splice site that is present in wild-
type individuals (Rodriguez et al., 2009;
Scaffidi and Misteli, 2006). Progerin RNA
and protein are detected in tissues from
healthy individuals, even before the
teenage years, albeit at levels 50-fold
lower than in HGPS cells. However, given
the dominant-negative nature of progerin,
these levels are likely sufficient to elicit
limited cellular damage. In addition, there
is histological evidence that progerin
levels may increase with age and may
be responsible for some of the cellular de-
fects associated with aging, which are
reminiscent of those seen in HGPS pa-
tients (McClintock et al., 2007). In support
of a potential dosage effect of progerin,
nonclassical progeria mutations that
induce less frequent use of the internal
splice site and thus lower cellular levels
of progerin also cause a much milder
form of disease but still eventually pro-
duce atherosclerosis (Hisama et al.,
2011). The extent to which lower levels
of progerin relative to HGPS can affect
health and aging is undetermined, but
evidence is accumulating to suggest a
role of progerin in many aspects of gener-
alized aging and cardiovascular health.
Notably, the atherosclerotic plaques in
HGPS are similar to those found in aging
individuals (Olive et al., 2010). Addition-
ally, vascular stiffening in progeria is
much like that seen over a lifetime of aging
reflected in each population by increased
pulse wave velocity (Gerhard-Herman
et al., 2012).
The cardiovascular system is of crucial
importance in HGPS, as cardiovascular
failure is the source of significant
morbidity and almost all mortality. From
a clinical perspective, HGPS is a primary
vasculopathy, characterized by early and
pervasive accelerated vascular stiffening
followed by hypertension, vessel plaques,
angina, cardiomegaly, metabolic syn-
drome, and congestive heart failure
(Baker et al., 1981). Isolated from risk fac-r Inc.tors such as hypercholesterolemia and
increased C-reactive protein (Gordon
et al., 2005), early stage hypertension,
and smoking, the study of HGPS could
provide an opportunity to discover new
elements that may influence the vascular
disease component of aging. For
example, the abnormally dense vascular
adventitia observed in individuals with
HGPS may contribute to their vessel stiff-
ening, and the role of the adventitia in the
pathobiology of generalized CVD during
aging is just beginning to be explored (Ha-
velka and Kibbe, 2011). Additionally,
HGPS has shed light on mechanisms of
vascular calcification in aging and athero-
sclerosis. Excess prelamin A or progerin
results in calcium dysfunction (Ragnauth
et al., 2010), and prelamin A promotes
VSMC calcification and aging by inducing
persistent DNA damage signaling (Liu
et al., 2013). HGPS patients suffer
from extraskeletal calcium phosphate
deposition, which potentially acts as an
important factor for vascular plaque
development (Cleveland et al., 2012).
These studies that show connections be-
tween cellular senescence, generalized
calcium dysfunction, vascular calcifica-
tion, and atherosclerotic plaque formation
in both aging and HGPS represent
emerging areas of cross-discovery in
both basic and clinical research arenas
(Mackenzie and MacRae, 2011).
Much like in normal aging, tissue stem
cell functions appear to be compromised
in HGPS (Espada et al., 2008; Rose-
ngardten et al., 2011; Scaffidi and Misteli,
2008). In a progeroid mouse model that
lacks the prelamin A endoprotease
ZMPSTE24 and recapitulates some phe-
notypes seen in HGPS, the proliferative
potential of epidermal stem cells is greatly
reduced (Espada et al., 2008). Further-
more, expression of progerin in human
mesenchymal stem cells triggers prema-
ture expression of lineage markers, albeit
in the absence of differentiation, but at the
same time interferes with differentiation
along defined lineages, including adipo-
genesis and osteogenesis (Scaffidi and
Misteli, 2008).
Notably, some key aspects of aging are
not recapitulated in HGPS. Most promi-
nent among these are the absence of
nervous system deterioration, including
dementia, and the lack of detectable im-
mune system deficits. Recent studies
Figure 2. A Spectrum of Possible HGPS Therapies
HGPS is amenable to a wide spectrum of cutting-edge therapeutic strategies.have shown that progerin levels in the
brain are very low and that the microRNA
miR-9 downregulates lamin A synthesis in
the brain (Jung et al., 2012; Nissan et al.,
2012). These results suggest that the
lack of symptoms in the CNS of HGPS
patientsmay be due to an absence of pro-
gerin in neural cells. This may also be the
case for the absence of immune system
deficiencies. Moreover, the paucity of
reports on tumors or cancers in HGPS
patients implies low susceptibility of their
cells to malignant transformation, in
contrast to the strong increase in tumor
susceptibility during normal aging. The
lack of tumors in HGPS patients is even
more surprising, given the persistently
high levels of DNA damage in HGPS cell
lines. Interestingly, recent studies using
ZMPSTE24 mosaic mice have revealed
that prelamin A accumulation prevents
cancer invasion and results in a decrease
in the incidence of infiltrating carcinomas
in association with altered extracellular
matrix components (de la Rosa et al.,
2013).
Like any premature aging syndrome,
HGPS is only a partial representation
of the multifactorial process of normal
aging. However, rather than using dis-
crepancies as an argument to diminish
the potential of HGPS to provide insight
into normal aging, a more productive
approach may be to carefully elucidate
the intersections and distinctions be-
tween HGPS and normal aging in order
to gain new understanding within both
fields.Progeria as a Testbed for
Therapeutic Strategies
The development of therapeutic strate-
gies for HGPS benefited from the conflu-
ence of gene discovery and extensive
prior knowledge of lamin A function at
the time of the gene discovery. This
made several therapeutic strategies
immediately apparent. Remarkably, the
time from gene discovery to the first hu-
man therapeutic trial for HGPS was just
5 years (Kieran et al., 2007). In the wake
of initial therapeutic trials, exponential
increases in our understanding of the dis-
easemechanisms combined with techno-
logical advances have broadened the
scope of both the potential therapeutic
targets and approaches (Figure 2). All of
the therapeutic strategies applied to
HGPS are under consideration for many
other diseases, and it is likely that experi-
enceswith HGPSwill prove relevant to the
larger medical community.
Drug Repurposing
Compared with developing any type of
new medication, drug repurposing, which
uses medications previously developed
for other diseases, promises the shortest
timeline from preclinical to clinical testing.
Discovering that progerin is permanently
farnesylated immediately opened the
door for a candidate drug discovery
approach using farnesyltransferase inhib-
itors (FTIs), which had previously been
developed as potential anticancer drugs
and had acceptable side effects in chil-
dren. FTIs were quickly and successfully
tested preclinically in cell culture (CapellCell 156et al., 2005; Glynn and Glover, 2005; Mal-
lampalli et al., 2005; Toth et al., 2005;
Yang et al., 2005) and animal models (Ca-
pell et al., 2008; Fong et al., 2006; Yang
et al., 2008), which showed improvement
of disease symptoms upon FTI treatment.
A prospective single-arm clinical trial was
initiated in 2007 with a cohort of 26 HGPS
patients between 3 and 16 years of age.
Administration of the FTI lonafarnib for a
minimum of 2 years yielded improve-
ments in weight gain, vascular stiffness,
and bone structure in some patients (Gor-
don et al., 2012) and provided evidence
for decreased headaches and strokes
(King and Heyer, 2013; Ullrich et al.,
2013), though the extent of improvements
varied among patients.
Subsequent to initiation of the first clin-
ical trial, it was reported that progerin
was partially modified in cultured HGPS
fibroblasts by geranylgeranylation after
FTI treatment (Varela et al., 2008). This
alternate modification could be blocked
by statins and aminobisphosphonates
that prevent the production of both farne-
syl and geranylgeranyl precursors (Varela
et al., 2008). This result offered one
possible explanation for why FTI treatment
only modestly lengthened lifespan in a
mouse model (Yang et al., 2008) and
prompted several currently ongoing thera-
peutic trials in which FTIs are combined
with pravastatin (a statin) and zoledronic
acid (an aminobisphosphonate). The
development of combination therapies
reflects a potentially powerful iterative
approach between basic and clinical, January 30, 2014 ª2014 Elsevier Inc. 403
sciences toward improving and optimizing
therapeutic strategies.
The drug-repurposing approach for
HGPS is still ongoing. One rationale is
that treatments with putative prolongevity
effects may also benefit children with
HGPS. For example, the macrolide antibi-
otic rapamycin, which extends lifespan
and improves stroke volume in several
model organisms, including aging mice
(Choi et al., 2012; Ramos et al., 2012),
has been shown to abolish nuclear struc-
ture defects and postpone senescence in
HGPS fibroblasts in cell culture by
enhancing progerin clearance through
autophagy (Cao et al., 2011b; Cenni
et al., 2011). Another compound of inter-
est is resveratrol, a SIRT1 activator that
interacts with lamin A (Liu et al., 2012). In
the presence of progerin, SIRT1 exhibits
reduced association with the nuclear ma-
trix and decreased deacetylase activity,
leading to rapid depletion of adult stem
cells in an HGPS model mouse. Treat-
ment with resveratrol improved cellular
phenotypes and extended lifespan in
this mouse model (Liu et al., 2012). Other
repurposed drug candidates are likely to
emerge, for example, non-steroidal anti-
inflammatory drugs, which may be useful
for blocking theNF-kB-signaling hyperac-
tivation observed in progeroid cells and
mouse models (Osorio et al., 2012).
New Drug Discovery Strategies
The HGPS etiology offers several points
of entry for drug discovery (Figure 2).
One potential avenue is the identification
of small molecular inhibitors of the aber-
rant pre-mRNA splicing event in HGPS.
But this is a challenging undertaking, as
no specifically acting small molecular
regulators of pre-mRNA splicing have
ever been reported. As a complementary
approach, imaging-based high-content
screens may be able to identify small
molecules that prevent the formation, or
promote the reversion, of HGPS cellular
phenotypes. Aberrant nuclear mor-
phology, DNA damage, or elimination of
the progerin protein may serve as read-
outs for these cell-based approaches in
drug discovery. HGPS patient-derived
iPS cells should prove a particularly useful
tool for such screens. New candidate
molecules from several such screens are
likely to be forthcoming shortly.
Similar to the farnesylation inhibitor
treatment strategy, another potential404 Cell 156, January 30, 2014 ª2014 Elsevietreatment avenue is based on our under-
standing of lamin A posttranslational
modifications. After farnesylation, the
last three amino acids of prelamin A and
progerin are cleaved, and the farnesylcys-
teine is methylated. Inhibition of the
posttranslational methylation step was
recently reported to improve HGPS
cellular senescence in vitro and amelio-
rated disease and early death in a proge-
roid mouse model (Ibrahim et al., 2013).
RNA Therapy
Because the HGPS mutation results from
the activation of an alternative pre-mRNA
splice site, HGPS is a prime candidate for
an RNA therapy approach via inhibition or
elimination of this site. Reversal of pheno-
type by inhibition of the altered splice site
was first achieved in HGPS fibroblasts by
treatment with a morpholino antisense
oligonucleotide targeted to the activated
splice site (Scaffidi and Misteli, 2005).
This strategy was successfully applied to
a knockin HGPS mouse model, resulting
in improved body weight, extended life-
span, and correction of several mutant
phenotypes (Osorio et al., 2011). An alter-
native approach is to eliminate the pro-
gerin mRNA using siRNA-based methods
(Huang et al., 2005). Although systemic
delivery of oligonucleotides and siRNAs
remains a challenge to these therapeutic
approaches, the availability of an appro-
priate animal model, an extensively clini-
cally characterized patient population,
and a clearly defined primary target tissue
(the vasculature) may make HGPS an
attractive case study for the development
of high-efficiency delivery methods for
these types of agents (Kole et al., 2012).
Stem Cell Treatment
Many of the alterations seen in HGPS are
consistent with stem cell dysfunction
(Halaschek-Wiener and Brooks-Wilson,
2007; Wenzel et al., 2012). In vitro, pro-
gerin affects the multipotency and differ-
entiation of human mesenchymal stem
cells (Scaffidi and Misteli, 2008), and
HGPS patient-derived iPS cells exhibit
differentiation defects (Zhang et al.,
2011). Furthermore, in a HGPS-related
cellular model, the proliferative potential
of epidermal stem cells was reduced
(Espada et al., 2008), and in an inducible
HGPS mouse model that specifically ex-
presses progerin in skin, the epidermal
population of adult stem cells was
depleted and wound healing impairedr Inc.(Rosengardten et al., 2011). This involve-
ment of tissue-stem cells in the HGPS
phenotype opens the possibility of cell-
based replacement therapies using either
matching wild-type cells or tissue-stem
cells generated from genetically cor-
rected HGPS iPS cells. Cell replacement
approaches face many challenges,
particularly in systemic diseases such as
HGPS. However, the prominence of the
vascular defects in HGPS may provide
an interesting model system to explore
the effectiveness of tissue-targeted ap-
proaches in systemic diseases.
Gene Therapy Approaches
As the progerin protein acts in a dominant
fashion and its effects cannot be compen-
sated by introduction of wild-type lamin A,
gene therapy for HGPS focuses on tar-
geted gene correction. For example,
zinc-finger, TALEN, or CRISPR-based ap-
proaches, in which the LMNA is repaired
ex vivo and corrected cells are re-intro-
duced into patients, is a possibility, albeit
a technically challenging one. As proof
of principle for the feasibility of this
approach, correction of the genetic defect
in HGPS patient-derived iPS cells and
their subsequent differentiation has been
achieved (Liu et al., 2011).
Challenges of Clinical Trials for
Rare Diseases
Rare diseases pose particular challenges
in designing and executing clinical trials.
Given that there are more than 6,800
rare diseases—about 80% of them with
a genetic basis—the lessons learned dur-
ing the rapid journey in HGPS from gene
identification to clinical trial may be of
value to other disease populations. The
very limited pool of patients with HGPS
required worldwide recruitment and orga-
nized communication with patient families
and their physicians through programs
such as international patient registries,
diagnostics programs, and continued
outreach to the patient community. For
optimal trial execution, these processes
must precede clinical trials by several
years. For HGPS, this recruitment was
achieved through a patient advocacy or-
ganization (The Progeria Research Foun-
dation), and the first clinical trial was fully
enrolled in under 4 months. Hospital-
based centers of excellence with similar
programs can also be useful for recruiting
patients to trials.
Due in part to the 100% fatality rate in
HGPS and in part to the extremely small
subject numbers (26 in the published
clinical trial), all human trials to date
have used open label design with no pla-
cebo control groups. In order to assess
drug efficacy, primary outcomemeasures
have relied upon a change in individual
patient status using each patient as
his or her own control (Gordon
et al., 2012) (ClinicalTrials.gov identifier:
NCT00425607). Designing appropriate
outcome measures required intensive
and ongoing natural history studies to
establish robust baseline values for each
clinical parameter in each individual pa-
tient. For any disease, investment into
natural history clinical trials, with the aim
of identifying longitudinal trends in dis-
ease-relevant and consistently evaluable
clinical abnormalities for use as treatment
trial outcome measures, is invaluable. In
addition, natural history studies are
remarkably insightful and powerful in un-
covering disease characteristics. For
example, some of the most relevant
vascular defects in HGPS were discov-
ered during baseline studies conducted
as part of the first clinical trial (Gerhard-
Herman et al., 2012; Gordon et al., 2011;
Silvera et al., 2013), which precluded their
inclusion as primary outcome measures
for trial drug efficacy but led the way for
improving detection of therapeutic effi-
cacy in future trials. The constraints and
approaches seen in the HGPS trials are
not unlike those in oncology trials for
rare, fatal pediatric cancers, wherein
similar challenges apply and similar trial
designs are used (Pui et al., 2011).
Future trials will need to grapple with
how to reliably measure changes in dis-
ease status in the face of combination
therapies whose implementation will
also further amplify the challenge of
recruiting sufficiently large patient popu-
lations for each treatment combination.
Although treatment outcomes have
been published for HGPS monotherapy
using lonafarnib (Gordon et al., 2012; Ull-
rich et al., 2013), its effects on patient
morbidity and mortality are not yet known
and will require longer-term patient expo-
sure. Given this, an important issue at
hand is whether it will be ethical and
statistically viable to conduct future trials
using a control arm with farnesylation
inhibitors and a treatment arm with farne-sylation inhibitors plus a new treatment of
interest.
Regulatory approval based on uncon-
trolled or small trials is a huge challenge,
as the U.S. Food and Drug Administration
(FDA) is responsible for evaluating safety
and efficacy and for weighing the risk-
to-benefit ratio with much less data than
what is supplied for common diseases.
Rare disease applications are the fastest
growing area of pharmaceutical and
biotechnical development. Unlike only
5 years ago, today there is an acute
awareness of rare diseases within the
FDA, which has identified the rare disease
space as a priority area. As a result, the
FDA has proactively created the Center
for Drug Evaluation and Research specif-
ically for Rare Diseases Drug Develop-
ment. In addition, the FDA and European
Medicines Agency Orphan Drug status is
designed to fast track what is usually a
very long process, without compromising
the quality of the review process.
Although increasing patient numbers
may not be an option, there is now a
regulatory body that can be consulted
specifically on recommendations for rare
disease treatment trials.
Looking Back and To the Future
Progress in the HGPS field has been
remarkably rapid over the last decade,
and if the most recent Progeria Research
Foundation Workshop is any indication,
there is no sign of slowdown. Many of
the hot topics in the field have both a
basic and translatable clinical compo-
nent, and the basic-clinical connection
will be driving much of the future work. A
recurrent theme was the emergence of
various candidate small molecules for
consideration in clinical trials, which has
been driven by our growing understand-
ing of the molecular and cellular mecha-
nisms affected in the disease.
Everyone wants to get to the finish
line—to cure patients with fatal diseases
and translate discoveries to the clinic.
Looking back over the past 10 years in
the progeria field, we see a roadmap for
how to optimize our chances of tackling
a disease once its molecular basis is un-
covered. Key elements to success are a
strong basic research foundation that
creates a detailed knowledge base of
the fundamental cellular disease process,
access to patient populations, andCell 156intense crosstalk between basic and clin-
ical investigators.
We have learned many important
lessons from a very rare disease, and
they will undoubtedly be applicable to
many other diseases, especially as the
rate with which disease-causing genes
are being identified is growing exponen-
tially due to the availability of powerful
genomic methods. Perhaps most impor-
tantly, the story of HGPS is yet another
example for how one can never predict
how scientific research on basic and
sometimes obscure-sounding topics,
such as farnesylation of a precursor to a
nuclear scaffold protein, may one day
become the key to better health for many.
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